Skip to content
10-Q

Quarterly Report

INTEGRATED BIOPHARMA INC INBP

0001437749-24-034953

← back to feed
Filed
Nov 13, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Nov 13, 2024 30.1M sh
Cash And Equivalents Q1 2025 · Sep 30, 2024 $2.27M
Cash And Equivalents Q1 2025 · Jun 30, 2024 $1.68M
Current Liabilities Q1 2025 · Sep 30, 2024 $6.03M
Current Liabilities Q1 2025 · Jun 30, 2024 $6.12M
Total Liabilities Q1 2025 · Sep 30, 2024 $6.63M
Total Liabilities Q1 2025 · Jun 30, 2024 $6.97M
Current Assets Q1 2025 · Sep 30, 2024 $18.31M
Current Assets Q1 2025 · Jun 30, 2024 $17.9M
Total Assets Q1 2025 · Sep 30, 2024 $26.18M
Total Assets Q1 2025 · Jun 30, 2024 $26.21M
Total Assets restated Q1 2025 · Jun 30, 2023 $26.21M
Shares Diluted Q1 2025 · Sep 30, 2023 29.97M sh
Capex Q1 2025 · Sep 30, 2023 $38K
Operating Cash Flow Q1 2025 · Sep 30, 2023 $1.31M
Stockholders Equity Q1 2025 · Sep 30, 2023 $18.89M
Stockholders Equity Q1 2025 · Jun 30, 2023 $18.86M
Eps Diluted Q1 2025 · Sep 30, 2023 $0.00
Eps Basic Q1 2025 · Sep 30, 2023 $0.00
Sga Expense Q1 2025 · Sep 30, 2023 $886K
Net Income Q1 2025 · Sep 30, 2023 −$59K
Operating Income Q1 2025 · Sep 30, 2023 −$54K
Gross Profit Q1 2025 · Sep 30, 2023 $832K
Cost Of Revenue Q1 2025 · Sep 30, 2023 $12.08M